Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03834584 · ClinicalTrials.gov registry record · Phase 1
A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma
A Phase 1 study, sponsored by Agios Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT03834584 is a Phase 1 study that was terminated before completion, run by Agios Pharmaceuticals. The registered enrollment target is 11 participants.
The verdict
NCT03834584, a Phase 1 study, was terminated before completion, sponsored by Agios Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This study will evaluate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of AG-636, an oral Dihydroorotate Dehydrogenase (DHODH) inhibitor, in subjects with advanced lymphoma.
Interventions
- DRUG AG-636
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2019-05-24 |
| Est. Completion | 2020-06-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03834584
The ClinicalTrials.gov registry entry for NCT03834584 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Agios Pharmaceuticals, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AG-636 is the first listed.
NCT03834584 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03834584 about?
NCT03834584 is a clinical study titled "A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma". This study will evaluate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of AG-636, an oral Dihydroorotate Dehydrogenase (DHODH) inhibitor, in subjects with advanced lymphoma.
What is the current status of trial NCT03834584?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2019-05-24. Estimated completion is 2020-06-17.
What interventions are being tested in trial NCT03834584?
The interventions under investigation include: AG-636 (DRUG).
Who is sponsoring clinical trial NCT03834584?
This trial is sponsored by Agios Pharmaceuticals, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.